Binh Dinh Pharmaceutical and Medical Equipment JSC
Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company manufactures and trades in pharmaceuticals and medical equipment in Vietnam. It offers antibiotics; anticancer drugs; hemodialysis solutions; hepatobiliary drugs; analgesic and antipyretic drugs; drugs for muscles, bones, and joints; antihistamine anti-allergy drugs; ear, eye, nose, and throat drops; cardiovascular drugs; nervous … Read more
Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) - Net Assets
Latest net assets as of December 2025: ₫1.72 Trillion VND
Based on the latest financial reports, Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) has net assets worth ₫1.72 Trillion VND as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₫2.58 Trillion) and total liabilities (₫862.89 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₫1.72 Trillion |
| % of Total Assets | 66.61% |
| Annual Growth Rate | 11.73% |
| 5-Year Change | 50.91% |
| 10-Year Change | N/A |
| Growth Volatility | 6.05 |
Binh Dinh Pharmaceutical and Medical Equipment JSC - Net Assets Trend (2020–2025)
This chart illustrates how Binh Dinh Pharmaceutical and Medical Equipment JSC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Binh Dinh Pharmaceutical and Medical Equipment JSC (2020–2025)
The table below shows the annual net assets of Binh Dinh Pharmaceutical and Medical Equipment JSC from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₫1.72 Trillion | +3.62% |
| 2024-12-31 | ₫1.66 Trillion | +15.93% |
| 2023-12-31 | ₫1.43 Trillion | +5.73% |
| 2022-12-31 | ₫1.36 Trillion | +18.81% |
| 2021-12-31 | ₫1.14 Trillion | +15.37% |
| 2020-12-31 | ₫988.63 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Binh Dinh Pharmaceutical and Medical Equipment JSC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₫528.88 Billion | 30.73% |
| Other Components | ₫1.19 Trillion | 69.27% |
| Total Equity | ₫1.72 Trillion | 100.00% |
Binh Dinh Pharmaceutical and Medical Equipment JSC Competitors by Market Cap
The table below lists competitors of Binh Dinh Pharmaceutical and Medical Equipment JSC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bonava AB B
LSE:0RHA
|
$183.30 Million |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
$183.33 Million |
|
Seven West Media Limited
PINK:WANHY
|
$183.39 Million |
|
Mayne Pharma Group Limited
PINK:MAYNF
|
$183.45 Million |
|
Rastar Environmental Protection Materials Co.Ltd.
SHE:300834
|
$183.26 Million |
|
Infortrend Technology Inc
TW:2495
|
$183.22 Million |
|
Shuhua Sports Co. Ltd.
SHG:605299
|
$183.22 Million |
|
Spectral Cap Corp
OTCQB:FCCN
|
$183.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Binh Dinh Pharmaceutical and Medical Equipment JSC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,661,140,815,718 to 1,721,205,987,753, a change of 60,065,172,035 (3.6%).
- Net income of 290,747,859,813 contributed positively to equity growth.
- Dividend payments of 188,829,462,575 reduced retained earnings.
- New share issuances of 9,355,000,000 increased equity.
- Other factors decreased equity by 51,208,225,203.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₫290.75 Billion | +16.89% |
| Dividends Paid | ₫188.83 Billion | -10.97% |
| Share Issuances | ₫9.36 Billion | +0.54% |
| Other Changes | ₫-51.21 Billion | -2.98% |
| Total Change | ₫- | 3.62% |
Book Value vs Market Value Analysis
This analysis compares Binh Dinh Pharmaceutical and Medical Equipment JSC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.86x to 2.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | ₫10567.23 | ₫51400.00 | x |
| 2022-12-31 | ₫14485.03 | ₫51400.00 | x |
| 2023-12-31 | ₫15315.61 | ₫51400.00 | x |
| 2024-12-31 | ₫17756.00 | ₫51400.00 | x |
| 2025-12-31 | ₫18215.89 | ₫51400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Binh Dinh Pharmaceutical and Medical Equipment JSC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.89%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.59%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.50x
- Recent ROE (16.89%) is below the historical average (17.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 15.97% | 12.56% | 0.87x | 1.45x | ₫59.00 Billion |
| 2021 | 16.58% | 12.13% | 1.00x | 1.37x | ₫75.07 Billion |
| 2022 | 17.97% | 15.66% | 0.82x | 1.40x | ₫108.04 Billion |
| 2023 | 18.78% | 16.29% | 0.83x | 1.39x | ₫125.77 Billion |
| 2024 | 16.57% | 15.93% | 0.76x | 1.36x | ₫109.07 Billion |
| 2025 | 16.89% | 15.59% | 0.72x | 1.50x | ₫118.63 Billion |
Industry Comparison
This section compares Binh Dinh Pharmaceutical and Medical Equipment JSC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,059,260,248,089
- Average return on equity (ROE) among peers: 16.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) | ₫1.72 Trillion | 15.97% | 0.50x | $183.29 Million |
| DHG Pharmaceutical JSC (DHG) | $3.57 Trillion | 20.74% | 0.25x | $29.78 Million |
| DOMESCO Medical Import Export JSC (DMC) | $1.25 Trillion | 18.58% | 0.22x | $21.40K |
| Imexpharm Corp (IMP) | $1.73 Trillion | 12.12% | 0.21x | $119.65 Million |
| Traphaco JSC (TRA) | $1.69 Trillion | 14.81% | 0.39x | $27.57 Million |